A Phase 1, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2018
At a glance
- Drugs AZD 5718 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 31 Aug 2018 Biomarkers information updated
- 14 Jun 2018 Status changed from recruiting to completed.
- 19 Mar 2018 Planned End Date changed from 31 May 2018 to 1 Jun 2018.